# BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients

> **NCT02051062** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **Emergent BioSolutions** · enrollment: 10 (estimated)

## Conditions studied

- Botulism

## Interventions

- **BIOLOGICAL:** Blood sample collection

## Key facts

- **NCT ID:** NCT02051062
- **Lead sponsor:** Emergent BioSolutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2014-10
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02051062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02051062, "BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients". Retrieved via AI Analytics 2026-08-08 from https://api.ai-analytics.org/clinical/NCT02051062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*